The Great Debate at ACR Convergence 2020 is: Janus Kinase Inhibitors Should/Should Not Be Used Before Biologics After Methotrexate Failure in RA. No need to hang in suspense. In this resource center, you’ll get the pros and cons, and highlights from other important sessions on rheumatoid arthritis (RA). Plus, you can explore our collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of RA.
A recently published study shows that inflammatory disease begins well before synovitis is seen on exam; a better understanding of what’s brewing before the storm could lead to the development of preventive therapies for RA.
Aydemir et al. examined the relationship between disease activity in rheumatoid arthritis (RA) and pain regulatory mechanisms of the central nervous system. They found that improvements in pain sensitivity were associated with reductions in disease activity in patients with RA after 12 weeks of treatment with disease-modifying anti-rheumatic drugs. This study underscores the importance of inflammatory and noninflammatory contributors to patient outcomes.
Experts identify barriers to shared decision making in rheumatology & offer actionable tools to integrate SDM into practice for better patient outcomes.
At this ACR Convergence Session, experts discussed brain fog experienced by many patients with rheumatic diseases & ways rheumatologists can help patients feel better supported.
At this ACR Convergence 2025 session, the speaker highlighted ways complementary and alternative medicine can be used alongside traditional medical treatments.
Experts discuss high-intensity interval training as an underused “disease-modifying drug” for inflammatory diseases. Learn how to safely integrate it into patient treatment plans.